Accepted Manuscript

Nanoparticle formulation improves doxorubicin efficacy by enhancing host antitumor immunity



Eric M. Mastria, Leon Y. Cai, Matthew J. Kan, Xinghai Li, Jeffrey L. Schaal, Steven Fiering, Michael D. Gunn, Mark W. Dewhirst, Smita K. Nair, Ashutosh Chilkoti

S0168-3659(17)31017-9
doi:10.1016/j.jconrel.2017.11.021
COREL 9051
Journal of Controlled Release
8 May 2017
15 October 2017
11 November 2017

Please cite this article as: Eric M. Mastria, Leon Y. Cai, Matthew J. Kan, Xinghai Li, Jeffrey L. Schaal, Steven Fiering, Michael D. Gunn, Mark W. Dewhirst, Smita K. Nair, Ashutosh Chilkoti, Nanoparticle formulation improves doxorubicin efficacy by enhancing host antitumor immunity. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Corel(2017), doi:10.1016/j.jconrel.2017.11.021

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Nanoparticle formulation improves doxorubicin efficacy by enhancing host antitumor immunity

Eric M. Mastria^a, Leon Y. Cai^a, Matthew J. Kan^b, Xinghai Li^a, Jeffrey L. Schaal^a, Steven Fiering^{g,h}, Michael D. Gunn^{b,d}, Mark W. Dewhirst^{a,c}, Smita K. Nair^{e,f}, and Ashutosh Chilkoti^{a,i*}

^aDepartment of Biomedical Engineering, Duke University, Durham, NC

Departments of ^bImmunology, ^cRadiation Oncology, ^dMedicine, ^eSurgery, and ^fPathology at Duke University Medical Center, Durham, NC

^{*g*}Department of Microbiology and Immunology, The Geisel School of Medicine at Dartmouth, Hanover, NH

^hNorris Cotton Cancer Center, Lebanon, NH

ⁱCenter for Biologically Inspired Materials and Materials Systems, Duke University, Durham, NC

***Corresponding Author:** Ashutosh Chilkoti, Fitzpatrick CIEMAS, 101 Science Drive, PO Box 90281, Department of Biomedical Engineering Duke University, Durham, NC, 27708-028, USA. Phone: 1-919-660-5373. Fax: 1-919-684-4488. E-mail: <u>chilkoti@duke.edu</u>

Disclosure of Potential Conflicts of Interest: A.C. has a financial interest in PhaseBio Pharmaceuticals, which has licensed the ELP technology from Duke University

CCC CCC

Download English Version:

https://daneshyari.com/en/article/7860772

Download Persian Version:

https://daneshyari.com/article/7860772

Daneshyari.com